Table 1.
Patients’ characteristics and drugs prescribed
| Characteristic | N = 90 |
|---|---|
| Sex | |
| Male; female | 39; 51 |
| Age (years) | |
| Mean (sd); range | 65 (10.92); 32–85 |
| Partner | |
| Yes | 58 |
| Employed | |
| Yes | 27 |
| Stage of disease | |
| III | 10 |
| IV | 80 |
| Past treatments | |
| Surgery | 51 |
| Chemotherapy | 44 |
| Radiotherapy | 31 |
| Hormone therapy | 13 |
| Treatment prescribed by tumour site | |
| Lung (30) | Afatinib (1) Carboplatin + etoposide (1) or gemcitabine (1) Pemetrexed + carboplatin (2) or cisplatin (2) Erlotinib (23) |
| Melanoma (19) | Ipilimumab (15) Dabrafenib (2) Vemurafenib (2) |
| Breast (18) | Bevacizumab + paclitaxel (2) Eribulin (6) Everolimus + exemestane (5) Trastuzumab emtansine TDM-1 (2) Pertuzumab + docetaxel + trastuzumab (3) |
| Renal (10) | Sunitinib (5) Pazopanib (2) Axitinib (2) Everolimus (1) |
| Gynae (7) | Bevacizumab (2) + carboplatin + paclitaxel (4) or + gemcitabine (1) |
| Head and neck (3) | Cetuximab + cisplatin (2) Cetuximab + carboplatin + 5FU (1) |
| Colorectal (2) | Bevacizumab (1) Bevacizumab + capecitabine (1) |
| Sarcoma (1) | Pazopanib (1) |
| Site of metastasis | |
| Lung | 45 |
| Bone | 23 |
| Liver | 19 |
| Brain | 7 |
| Lymph nodes | 19 |